The company has not filed an annual or quarterly report since its FY2019 10-K, filed Mar 20, 2020. Its latest SEC filing is a 15-12B from Apr 17, 2020.
10-K for FY2019, filed Mar 20, 2020
The sections below describe the company as of the FY2019 annual report.
Develops antibody treatments for people with cancer, including magrolimab, and antibody-based conditioning treatments for stem-cell transplantation.
10-K for FY2019, filed Mar 20, 2020
Partners pay for licenses to the company's intellectual property through an upfront amount, with possible future milestone payments and royalties. The license payment is tied to when the partner can use and benefit from the license.
10-K for FY2019, filed Mar 20, 2020
$15.7M
10-K for FY2019, filed Mar 20, 2020
$15.7M ↗
License and research-collaboration partners include Ono, bluebird bio, and Rocket Pharmaceuticals. The company planned to build its own sales capabilities in the United States and European Union and use third-party partners in other markets if products were approved.
10-K for FY2019, filed Mar 20, 2020The Company accounts for the Ono Agreement as a collaboration arrangement under ASC 808. The Company concluded that the license delivered…View ↗
In September 2019, we entered into a research collaboration with bluebird bio, Inc. (“bluebird”) to pursue clinical proof-of-concept for…View ↗
In March 2020, we announced a research collaboration with Rocket Pharmaceuticals to pursue clinical proof-of-concept for Forty Seven’s…View ↗
Given our stage of development, we have not yet established a commercial organization or distribution capabilities. We plan to build…View ↗
No. It lost $87.6M in FY2019.
10-K for FY2019, filed Mar 20, 2020
8-K, filed Apr 7, 2020
As described in the Introductory Note above, on April 7, 2020, Purchaser irrevocably accepted for payment all Shares validly tendered and…View ↗
Competes with Celgene, Trillium Therapeutics, ALX Oncology, Arch Oncology, Surface Oncology, Novimmune, OSE Immunotherapeutics, Innovent, I-MAB BIOPHARMA, Aurigene Discovery Technologies, Magenta, Jasper, and Amgen
10-K for FY2019, filed Mar 20, 2020We are aware that Celgene Corporation, Trillium Therapeutics, ALX Oncology, Arch Oncology, Surface Oncology, Novimmune, OSE…View ↗
Loading...
